SEC Filing Summary
Entity note: Although the request metadata names Cypherpunk Technologies Inc., the supplied Form 10-Q is for Leap Therapeutics, Inc. (Nasdaq: LPTX), filed for the quarter ended June 30, 2019.
Business context and reporting period
Leap is a clinical-stage biopharmaceutical company developing cancer therapies. Its two clinical-stage candidates are DKN-01, targeting DKK1, and TRX518, targeting GITR. Neither candidate was FDA-approved, and the company reported no product revenue. Financial statements are unaudited and cover the three and six months ended June 30, 2019, with comparisons to 2018.
Financial performance and position
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Revenue | No product revenue | No product revenue | No product revenue | No product revenue |
| Research and development expense | $6.1 million | $4.2 million | $12.9 million | $8.5 million |
| General and administrative expense | $2.3 million | $2.6 million | $4.3 million | $4.7 million |
| Net loss | $8.4 million | $7.4 million | $17.0 million | $18.0 million |
| Net loss per share | $0.37 | $0.50 | $0.82 | $1.32 |
| Cash used in operating activities | Not provided for quarter | Not provided for quarter | $14.1 million | $11.5 million |
At June 30, 2019, cash and cash equivalents were $15.7 million; current assets were $16.8 million and current liabilities $8.5 million. Total liabilities were $9.2 million, including $1.4 million of lease liabilities; the filing reports no borrowing debt. Stockholders’ equity was $10.9 million and accumulated deficit was $179.2 million. The company recorded no gross profit or operating margin because it had no product revenue.
Cash declined by $0.5 million in the first half, as $13.6 million of financing proceeds largely offset operating and investing cash use. The company also expected $0.8 million of Australian R&D incentive payments in 2019; $0.97 million was receivable at quarter-end.
Material changes versus prior period
- Q2 R&D expense rose $1.9 million year over year, primarily from higher clinical trial costs and patient enrollment; TRX518 program spending increased while DKN-01 spending decreased for the quarter.
- First-half R&D expense rose $4.5 million, with increases in both DKN-01 and TRX518 spending. Management cited higher trial activity, consulting and personnel costs, partly offset by lower manufacturing costs due to timing.
- First-half net loss narrowed by about $1.0 million, despite higher operating expenses, mainly because the 2018 period included a $5.5 million noncash warrant fair-value loss. Australian R&D incentive income also fell by $0.8 million.
- February 2019 public offering raised approximately $12.1 million net and issued 7.6 million shares, each with a warrant. First-half ATM sales raised approximately $1.3 million net. Common shares outstanding increased to 22.9 million at June 30, from 14.7 million at year-end 2018.
Outlook, risks and unusual items
- Management expects operating losses and R&D spending to continue and anticipates R&D expense may increase, subject to available funding. No quantified revenue, earnings, or cash-flow guidance was provided.
- The filing states that substantial doubt exists about the company’s ability to continue as a going concern for one year after issuance of the financial statements, due to its need for additional capital and uncertainty about raising it. Without funding or cost-sharing, the company may delay, reduce, or eliminate trials and other programs.
- After quarter-end, Leap obtained the right to sell up to $20 million of stock to Lincoln Park over 24 months, subject to conditions and limits; it also agreed to sell 571,429 shares for $1 million. It issued 330,000 commitment shares without cash proceeds and reported July ATM proceeds of $0.35 million. These financings may dilute shareholders.
- Management reported preliminary KEYNOTE-731 combination results in small evaluable groups: DKK1-high patients had a 50% response rate among 10 patients, while DKK1-low patients had a 20% disease control rate among 15. These are clinical findings, not approved-product results, and require confirmation.
- TRX518 enrollment began in a triple-combination study with cyclophosphamide and avelumab; dose escalation was ongoing. DKN-01 gynecological-cancer enrollment continued, with 96 patients enrolled overall.
- Two European patent opposition matters involving TRX518 remained under appeal; one related patent had been revoked by the opposition division. The potential outcome and any financial effect are not quantified.
- ASU 2017-11 changed accounting for the 2017 warrants: $3.45 million was reclassified from warrant liability to equity, and a $0.36 million dividend attributable to the down-round feature reduced income available to common stockholders in first-half EPS. The company also adopted lease accounting, recording lease assets and liabilities.
Important facts for investors to verify
- How much of the Lincoln Park facility can be accessed under its conditions, and the likely share-price and dilution effects of future sales.
- Cash runway and subsequent cash use, given the going-concern warning and continuing operating losses.
- Whether DKN-01 and TRX518 trial findings are reproducible in larger studies and progress toward regulatory milestones.
- Status and potential impact of the TRX518 patent appeals and the company’s other intellectual-property protections.
- Timing and collection of Australian R&D incentives, and the extent to which reported receivables are realized as cash.